Cytomegalovirus Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for cytomegalovirus infection. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
8
Active US patents
27/100
Avg vulnerability
$978M
Annual revenue covered

Originators in Cytomegalovirus Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating cytomegalovirus infection. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
29
2
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Prevymis
LETERMOVIR
Merck & Co. 8 27 $978M 2029-01-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10603384 Prevymis formulation 42 2033-02-28
10603384 Prevymis formulation 42 2033-02-28
RE46791 Prevymis composition of matter 30 2029-01-18
RE46791 Prevymis composition of matter 30 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 17 2029-01-18
RE46791 Prevymis composition of matter 30 2029-01-18
RE46791 Prevymis composition of matter 30 2029-01-18
10603384 Prevymis formulation 42 2033-02-28
10603384 Prevymis formulation 42 2033-02-28

Related